Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK46 Inhibition
Joint Authors
Borges, Virginia F.
Schedin, Troy B.
Shagisultanova, Elena
Source
International Journal of Breast Cancer
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-06-19
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Triple positive breast cancers overexpress both the human epidermal growth factor receptor 2 (HER2) oncogene and the hormonal receptors (HR) to estrogen and progesterone.
These cancers represent a unique therapeutic challenge because of a bidirectional cross-talk between the estrogen receptor alpha (ERα) and HER2 pathways leading to tumor progression and resistance to targeted therapy.
Attempts to combine standard of care HER2-targeted drugs with antihormonal agents for the treatment of HR+/HER2+ breast cancer yielded encouraging results in preclinical experiments but did improve overall survival in clinical trial.
In this review, we dissect multiple mechanisms of therapeutic resistance typical of HR+/HER2+ breast cancer, summarize prior clinical trials of targeted agents, and describe novel rational drug combinations that include antihormonal agents, HER2-targeted drugs, and CDK4/6 inhibitors for treatment of the HR+/HER2+ breast cancer subtype.
American Psychological Association (APA)
Schedin, Troy B.& Borges, Virginia F.& Shagisultanova, Elena. 2018. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK46 Inhibition. International Journal of Breast Cancer،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1169470
Modern Language Association (MLA)
Schedin, Troy B.…[et al.]. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK46 Inhibition. International Journal of Breast Cancer No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1169470
American Medical Association (AMA)
Schedin, Troy B.& Borges, Virginia F.& Shagisultanova, Elena. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK46 Inhibition. International Journal of Breast Cancer. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1169470
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1169470